CD19 and neoplasm: For instance, when administrating CD19 CAR-T cell in patients with malignant B cells, the on-target/off-tumor effect will lead to B cell aplasia and result in hypogammaglobulinemia due to the eradication of CD19+ B cell progenitors by CD19 CAR T cells (71, 72).